{
    "2021-04-05": [
        [
            {
                "time": "",
                "original_text": "里昂：一举升复星医药评级至买入 目标价上调至43.56港元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "评级",
                        "买入",
                        "目标价",
                        "上调"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业一周观察：调整后重归均衡 关注内生成长明确的一二线公司",
                "features": {
                    "keywords": [
                        "医药行业",
                        "调整",
                        "均衡",
                        "内生成长",
                        "一二线公司"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}